Research & Development
At USCAP 2023, ProPhase Labs to present data about esophageal cancer screening test
The upcoming presentation in New Orleans is scheduled for March 14 and entitled "Targeted Mass Spectrometry of Barrett's Esophagus Reveals High-Fidelity Combinatorial Molecular Correlates."
March 13, 2023
Study evaluates Prophase Labs test for esophageal cancer
The study authors note that early detection, especially through noninvasive biomarker-based tests such as Prophase Labs' BE-Smart test, is critical to improving outcomes for esophageal cancer.
February 16, 2023
Lucid Diagnostics study demonstrates esophageal cell sampling in office setting
More than 90% of samples collected yielded DNA to perform molecular biomarker testing using the company’s EsoGuard Esophageal DNA test.
December 1, 2022
CDx Diagnostics, Avalon ink in-network lab agreement
The agreement makes CDx's diagnostic platform, WATS3D, available to the 565,000 members of BCBS of South Carolina, including all of its commercial and Medicare Advantage plans.
June 13, 2022
Lucid’s LucidDx Labs signs deal with MediNcrease
This is Lucid's first agreement with a commercial payer. The deal will provide in-network access and payment for Lucid's EsoGuard DNA test to those insured by MediNcrease. The health insurance plan currently provides coverage to 8 million people.
May 8, 2022
Lucid promotes new guideline from ACG on esophageal cancer
The new guidelines include a reference to screening for esophageal cancer using Lucid's EsoGuard DNA test on samples collected with its EsoCheck Cell Collection device, it said.
April 3, 2022
Castle's esophagus test nabs ADLT status
The test aims to predict whether patients with Barrett's esophagus will develop esophageal cancer or high-grade dysplasia. The status was effective March 24.
March 29, 2022
Lucid launches 3 new test centers
The test centers are staffed with Lucid-employed nurse practitioners who use Lucid's EsoCheck cell collection device to collect surface esophageal cells. Then, the cells undergo Lucid's EsoGuard DNA esophageal test.
March 22, 2022
Castle Biosciences completes Cernostics acquistion
The acquisition expands Castle's offerings to include Cernostics' TissueCypher Barrett's Esophagus Assay, a test that predicts future development of high-grade dysplasia and/or esophageal cancer in patients with Barrett's esophagus, it said.
December 5, 2021
Agilent secures expanded CE Mark for cancer assay
The test may now be used to identify esophageal cancer patients eligible for treatment with Keytruda, a monoclonal antibody developed by Merck that boosts the body's ability to fight cancer cells.
August 22, 2021
Page 1 of 1